Mobile

A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, adva...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003220-19

A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer who have experienced disease progression during platinum-based chemotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine if the administration of Tarceva™ after disease progression on standard platinum-based chemotherapy in the treatment of NSCLC results in improved overall survival when compared to Alimta® (pemetrexed) or Taxotere® (docetaxel).

Critère d'inclusion

  • Advanced (stage IIIB or IV) non-small cell lung cancer (NSCLC) previously treated with a platinum-based chemotherapy

Liens